Key Details
Price
$0.77Annual Revenue
$651.00 KAnnual ROE
-102.44%Beta
0.45Events Calendar
Next earnings date:
Mar 06, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 06, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Oct 26, 2022Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Talphera, Inc. (NASDAQ:TLPH ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - Chief Medical Officer Conference Call Participants James Molloy - Alliance Global Partners Thomas Yip - H.C. Wainwright Operator Welcome to the Talphera Third Quarter 2024 Financial Results Conference Call.
SAN MATEO, Calif., Oct. 8, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit and will be available for 1x1 meetings with registered investors.
The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational trial in 166 patients at up to 14 clinical sites Primary endpoint in the NEPHRO CRRT study is measured over the first 24 hours, with patients completing the study after 72 hours Dr. Stuart Goldstein, a world-renowned nephrologist, is the first physician to enroll a patient in the NEPHRO CRRT study SAN MATEO, Calif. , Aug. 19, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the first patient has been enrolled in the NEPHRO CRRT study.
SAN MATEO, Calif. , Aug. 5, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2024 financial results after market close on Wednesday, August 14, 2024, then host a live webcast and conference call at 4:30 p.m.
SAN MATEO, Calif. , May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company specializing in developing and selling innovative therapies for medically supervised use, announced today that its management will take part in a fireside chat at the A.G.P.
FAQ
- What is the primary business of Talphera?
- What is the ticker symbol for Talphera?
- Does Talphera pay dividends?
- What sector is Talphera in?
- What industry is Talphera in?
- What country is Talphera based in?
- When did Talphera go public?
- Is Talphera in the S&P 500?
- Is Talphera in the NASDAQ 100?
- Is Talphera in the Dow Jones?
- When was Talphera's last earnings report?
- When does Talphera report earnings?
- Should I buy Talphera stock now?